6.50
6.50 (0%)
As of Feb 14, 2025
Eyepoint Pharmaceuticals, Inc. [EYPT]
Source:
Company Overview
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases.
| Country | United States |
| Headquarters | watertown, massachusetts |
| Phone Number | 617-926-5000 |
| Industry | manufacturing |
| CEO | Jay S. Duker, M.D. |
| Website | www.eyepointpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $43.3 |
| Operating Profit | $-145.9 |
| Net Income | $-130.9 |
| Net Cash | $-181.6 |
Profit Ratios
| Gross Margin | $39.6 |
| Operating Margin | -337.1 |
| Profit as % of Revenues | -30.2% |
| Profit as % of Assets | -33.8% |
| Profit as % of Stockholder Equity | -38.9% |
Management Effectiveness
| Return on Equity | -38.9% |
| Return on Assets | -31.3% |
| Turnover Ratio | 11.2% |
| EBITA | $-145.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $418.5 |
| Total Liabilities | $82 |
| Operating Cash Flow | $-126.2 |
| Investing Cash Flow | $-219.4 |
| Financing Cash Flow | $164 |
